The c-Jun N-terminal kinase (JNK) inhibitor XG-102 enhances the neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats

Neuropathol Appl Neurobiol. 2010 Apr;36(3):211-24. doi: 10.1111/j.1365-2990.2009.01047.x. Epub 2009 Oct 22.

Abstract

Aim: Both hyperbaric oxygenation (HBO) and inhibition of the c-Jun N-terminal kinases (JNKs) by the peptide inhibitor XG-102 (D-JNKI-1) are efficient protective strategies against ischaemia-induced neurodegeneration. The present study investigated whether the combination of HBO and JNK inhibitor, XG-102, provides additive neuroprotection against cerebral ischaemia.

Methods: Rat middle cerebral artery was occluded (MCAO) for 90 min. XG-102 [2 mg/kg, intraperitoneally] or HBO (3 ATA, 60 min) was applied 3 h after the onset of MCAO. For the combination treatment, HBO was started 10 min after the injection of XG-102. Twenty-four hours after MCAO, the infarct area, the neurological score and the immunohistochemistry staining in brain slices for cleaved-PARP, transferase-mediated biotinylated UTP nick end labelling, c-Jun and phosphorylated (activated) c-Jun were observed.

Results: XG-102 or HBO alone reduced the total infarct area by 43% and 63%, respectively. The combination diminished total infarct area by 78%, improved the neurological function and reduced brain oedema. Co-application of HBO and XG-102 also significantly reduced the cleavage of PARP, by 96% and 91% in cortical penumbra and ischaemic core, respectively. Moreover, cotreatment significantly attenuated the number of cells labelled with transferase-mediated biotinylated UTP nick end labelling and phosphorylated c-Jun.

Conclusion: Our study demonstrates that HBO reinforces the efficiency of neuroprotective drugs such as XG-102 and vice versa. Both treatments, physical HBO and pharmacological XG-102, are already in phase I/II studies and promising strategies for clinical use.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Brain Edema / drug therapy
  • Brain Edema / pathology
  • Brain Edema / therapy
  • Brain Ischemia / drug therapy
  • Brain Ischemia / pathology
  • Brain Ischemia / therapy
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use*
  • Hyperbaric Oxygenation / methods*
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Infarction, Middle Cerebral Artery / therapy*
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Male
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Phosphorylation
  • Proto-Oncogene Proteins c-jun / metabolism
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors

Substances

  • Enzyme Inhibitors
  • Neuroprotective Agents
  • Peptides
  • Proto-Oncogene Proteins c-jun
  • JNK Mitogen-Activated Protein Kinases
  • D-JNKI-1